1g37: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:
|PDB= 1g37 |SIZE=350|CAPTION= <scene name='initialview01'>1g37</scene>, resolution 2.0&Aring;
|PDB= 1g37 |SIZE=350|CAPTION= <scene name='initialview01'>1g37</scene>, resolution 2.0&Aring;
|SITE=  
|SITE=  
|LIGAND= <scene name='pdbligand=110:3-(4-AMINO-CYCLOHEXYL)-2-HYDROXY-3-[(4-OXO-2-PHENYLMETHANESULFONYL-1,2,3,4-TETRAHYDRO-PYRROLO[1,2-A]PYRAZINE-6-CARBONYL)-AMINO]-PROPIONIC ACID BUTYL ESTER'>110</scene>
|LIGAND= <scene name='pdbligand=110:3-(4-AMINO-CYCLOHEXYL)-2-HYDROXY-3-[(4-OXO-2-PHENYLMETHANESULFONYL-1,2,3,4-TETRAHYDRO-PYRROLO[1,2-A]PYRAZINE-6-CARBONYL)-AMINO]-PROPIONIC+ACID+BUTYL+ESTER'>110</scene>
|ACTIVITY= [http://en.wikipedia.org/wiki/Thrombin Thrombin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.5 3.4.21.5]  
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Thrombin Thrombin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.5 3.4.21.5] </span>
|GENE=  
|GENE=  
|DOMAIN=
|RELATEDENTRY=
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1g37 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1g37 OCA], [http://www.ebi.ac.uk/pdbsum/1g37 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1g37 RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
Bicyclic piperazinone based thrombin inhibitors of general structure 2 were prepared and evaluated in vitro and in vivo. These inhibitors, having in common an electrophilic basic trans-cyclohexylamine P1 residue, displayed high thrombin affinity, high selectivity against trypsin and good in vivo efficacy in the rat arterial thrombosis model.
Bicyclic piperazinone based thrombin inhibitors of general structure 2 were prepared and evaluated in vitro and in vivo. These inhibitors, having in common an electrophilic basic trans-cyclohexylamine P1 residue, displayed high thrombin affinity, high selectivity against trypsin and good in vivo efficacy in the rat arterial thrombosis model.
==Disease==
Known diseases associated with this structure: Dysprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hyperprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hypoprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]]


==About this Structure==
==About this Structure==
Line 33: Line 33:
[[Category: Tarazi, M.]]
[[Category: Tarazi, M.]]
[[Category: Winocour, P D.]]
[[Category: Winocour, P D.]]
[[Category: 110]]
[[Category: inhibitor]]
[[Category: inhibitor]]
[[Category: protease]]
[[Category: protease]]
[[Category: thrombin]]
[[Category: thrombin]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 11:17:35 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 20:35:35 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA